MyFinsight
Home
Blog
About
Comprehensive gain
-$34,852K
(-173.91%↓ Y/Y)
Foreign currency
translation gain (loss)
$470K
(75.37%↑ Y/Y)
FILSPARI
$141,078K
Tiopronin Products
$20,274K
Net gain
-$34,797K
(-172.81%↓ Y/Y)
Unrealized loss on
marketable debt securities
-$525K
(-121.52%↓ Y/Y)
Product
$161,352K
(70.13%↑ Y/Y)
License
$8,232K
(-58.01%↓ Y/Y)
Loss from continuing
operations, net of tax
-$34,797K
(-172.81%↓ Y/Y)
Income tax benefit
(provision) on continuing...
-$204K
(-1120.00%↓ Y/Y)
Total revenue
$169,584K
(48.17%↑ Y/Y)
Loss from continuing
operations before income...
-$35,001K
(-174.84%↓ Y/Y)
Operating income (loss)
$3,954K
(131.26%↑ Y/Y)
Total operating
expenses
$165,630K
(30.32%↑ Y/Y)
Total other (expense)
income, net
-$38,955K
(-45729.41%↓ Y/Y)
Interest income
$3,356K
(2.10%↑ Y/Y)
Selling, general and
administrative
$96,112K
(26.10%↑ Y/Y)
Research and development
$60,283K
(22.12%↑ Y/Y)
Royalty expense
$7,061K
Cost of goods sold
$2,174K
(42.93%↑ Y/Y)
Inducement expense
$40,008K
Interest expense
$2,134K
(-25.02%↓ Y/Y)
Other (expense)
income, net
-$169K
(67.87%↑ Y/Y)
Back
Back
Income Statement
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)
source: myfinsight.com